919366-47-5

Usage

Uses

Used in Pharmaceutical Industry:
1(2H)-Pyridinecarboxylic acid, 2-(cyclohexylmethyl)-5-[(2,6-dichlorophenyl)methyl]-3,4-dihydro-6-methyl-4-oxo-, phenylmethyl ester is used as a potential pharmaceutical compound for its possible pharmacological properties. Its specific application and effectiveness would need to be determined through further research and testing.
Used in Chemical Research:
In the field of chemical research, 1(2H)-Pyridinecarboxylic acid, 2-(cyclohexylmethyl)-5-[(2,6-dichlorophenyl)methyl]-3,4-dihydro-6-methyl-4-oxo-, phenylmethyl ester can be used as a starting material or a model compound for studying the effects of its unique structural features on its chemical and biological properties. This may lead to the development of new drugs or a better understanding of its potential applications in various industries.

Upstream product

• 919366-45-3 4-cyclohexylmethoxy-3-(2,6-dichlorobenzyl)-2-methylpyridine 
• 35166-78-0 cyclohexylmethyl magnesium bromide 
• 501-53-1 benzyl chloroformate 
• 478246-05-8 3-(2,6-dichlorobenzyl)-2-methylpyridin-4(1H)-one 
• 190906-91-3 3,4-dihydro-2-methyl-4-oxo-1(2H)-pyridinecarboxylic acid phenylmethyl ester 
• 909867-62-5 1-benzyloxycarbonyl-3-((2,6-dichlorophenyl)(methylsulfonyloxy)methyl)-2,3-dihydro-2-methylpyridin-4(1H)-one 
• 909867-58-9 1-benzyloxycarbonyl-3-((2,6-dichlorophenyl)hydroxymethyl)-2,3-dihydro-2-methylpyridin-4(1H)-one 
• 620-08-6 4-methoxypyridine 

Downstream Products

• 919366-49-7 C₂₈H₂₉Cl₂NO₃ 

Relevant academic research and scientific papers

4-Pyridone derivatives as new inhibitors of bacterial enoyl-ACP reductase FabI

Bacterial FAS provides essential fatty acids for use in the assembly of key cellular components. Among them, FabI is an enoyl-ACP reductase which catalyzes the final and rate-limiting step of bacterial FAS. It is a potential target for selective antibacterial action, because it shows low overall sequence homology with mammalian enzymes. Until today, various compounds have been reported as inhibitors of bacterial FabI-inhibitory compounds. To discover novel small-molecular FabI inhibitors, we initially screened our compound library for inhibitory activity toward FabI of Escherichia coli. And discovered 4-pyridone derivatives as a lead compound. Structure optimization studies yielded 4-pyridone derivatives 7n having strong FabI-inhibitory and antibacterial activities against Staphylococcus aureus. There have been no reports concerning 4-pyridone derivatives as FabI inhibitor.